Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MAP4K4-IN-3 (Compound 17) may be a viable target for antidiabetic agents, a serine/threonine protein kinase.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 39.00 | |
10 mg | In stock | $ 72.00 | |
25 mg | In stock | $ 155.00 | |
50 mg | In stock | $ 247.00 | |
100 mg | In stock | $ 393.00 | |
200 mg | In stock | $ 582.00 | |
500 mg | In stock | $ 885.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 43.00 |
Description | MAP4K4-IN-3 (Compound 17) may be a viable target for antidiabetic agents, a serine/threonine protein kinase. |
Targets&IC50 | MAP4K4:14.9 nM |
In vitro | MAP4K4-IN-3, Antidiabetic agent.MAP4K4-IN-3 is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay. |
In vivo | Administering MAP4K4-IN-3 (Compound 2; 25 mg/kg, b.i.d.) orally to telemetered rats over a period of five days induces several adverse reactions. Cardiovascular measurements reveal a significant increase in maximal heart rate by 25 beats per minute (bpm) compared to control groups upon treatment with MAP4K4-IN-3[2]. Additionally, there are noticeable declines in body weight (7%) and an increase in body temperature (0.4°C) against control values throughout the study. |
Synonyms | Compound 17 |
Molecular Weight | 297.74 |
Formula | C15H12ClN5 |
CAS No. | 1811510-58-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 8 mg/mL (26.87mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MAP4K4-IN-3 1811510-58-3 MAPK Compound 17 MAP4K MAPK Kinase Kinase Kinase Inhibitor MAP4K4 IN 3 MAP4K4IN3 inhibit MAP-4K4-IN-3 inhibitor